Ziftomenib (KO-539) is an oral inhibitor of menin targeting the menin–KMT2A protein-protein interaction. It exhibits antileukemic activity and induces apoptosis of acute myeloid leukemia(AML) cells.

Inaxaplin (VX-147) is an orally active inhibitor of apolipoprotein L1 (APOL1) function. Inaxaplin binds to APOL1 and is useful in the treatment of APOL1-associated kidney disease.

Ziftomenib (KO-539) is an oral inhibitor of menin targeting the menin–KMT2A protein-protein interaction. It exhibits antileukemic activity and induces apoptosis of acute myeloid leukemia(AML) cells.

Inaxaplin (VX-147) is an orally active inhibitor of apolipoprotein L1 (APOL1) function. Inaxaplin binds to APOL1 and is useful in the treatment of APOL1-associated kidney disease.

Inaxaplin (VX-147) is an orally active inhibitor of apolipoprotein L1 (APOL1) function. Inaxaplin binds to APOL1 and is useful in the treatment of APOL1-associated kidney disease.

ACHP Hydrochloride (IKK-2 Inhibitor VIII) is a highly potent and selective IKK-β inhibitor with an IC50 of 8.5 nM.

Inaxaplin (VX-147) is an orally active inhibitor of apolipoprotein L1 (APOL1) function. Inaxaplin binds to APOL1 and is useful in the treatment of APOL1-associated kidney disease.

Mal-amido-PEG2-C2-amido-Ph-C2-CO-AZD (Mal-PEG2-AZD) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

SRI-37330 HCl(EX-A5854), an anti-diabetic drug, is an orally bioavailable inhibitor of thioredoxin-interacting protein (TXNIP), with an IC50 of 0.64 μM for TXNIP expression in INS-1 cells. Its treatment inhibits glucagon secretion and function, decreases hepatic glucose production, and reverses hepatic steatosis.

SRI-37330 HCl(EX-A5854), an anti-diabetic drug, is an orally bioavailable inhibitor of thioredoxin-interacting protein (TXNIP), with an IC50 of 0.64 μM for TXNIP expression in INS-1 cells. Its treatment inhibits glucagon secretion and function, decreases hepatic glucose production, and reverses hepatic steatosis.